2024
Glucagon promotes increased hepatic mitochondrial oxidation and pyruvate carboxylase flux in humans with fatty liver disease
Petersen K, Dufour S, Mehal W, Shulman G. Glucagon promotes increased hepatic mitochondrial oxidation and pyruvate carboxylase flux in humans with fatty liver disease. Cell Metabolism 2024, 36: 2359-2366.e3. PMID: 39197461, DOI: 10.1016/j.cmet.2024.07.023.Peer-Reviewed Original ResearchRNA modifications in the progression of liver diseases: from fatty liver to cancer
Li S, Mehal W, Ouyang X. RNA modifications in the progression of liver diseases: from fatty liver to cancer. Science China Life Sciences 2024, 67: 2105-2119. PMID: 38809498, PMCID: PMC11545962, DOI: 10.1007/s11427-023-2494-x.Peer-Reviewed Original ResearchRNA modificationsRNA metabolismRNA speciesNon-alcoholic fatty liver diseaseN1-methyladenosineCellular functionsN6-methyladenosineGene expressionRNANon-alcoholic steatohepatitisFatty liver to non-alcoholic steatohepatitisM6AHepatocellular carcinomaGlobal health concernFatty liver diseaseLiver diseaseM5CHigher risk of metabolic syndromePseudouridineAssociated with higher risk of metabolic syndromePathological conditionsRisk of metabolic syndromeGenes-methyladenosineProgression of liver disease
2023
Humanized mouse liver reveals endothelial control of essential hepatic metabolic functions
Kaffe E, Roulis M, Zhao J, Qu R, Sefik E, Mirza H, Zhou J, Zheng Y, Charkoftaki G, Vasiliou V, Vatner D, Mehal W, AlcHepNet, Kluger Y, Flavell R. Humanized mouse liver reveals endothelial control of essential hepatic metabolic functions. Cell 2023, 186: 3793-3809.e26. PMID: 37562401, PMCID: PMC10544749, DOI: 10.1016/j.cell.2023.07.017.Peer-Reviewed Original ResearchConceptsMetabolic functionsSpecies-specific interactionsKey metabolic functionsCell-autonomous mechanismsNon-alcoholic fatty liver diseaseMajor metabolic hubNon-parenchymal cellsMetabolic hubHuman hepatocytesMicroenvironmental regulationHuman diseasesHuman-specific aspectsHuman pathologiesHomeostatic processesSpecies mismatchCholesterol uptakeFatty liver diseaseParacrine mannerHuman immuneBile acid conjugationSinusoidal endothelial cellsHepatic metabolic functionMouse liverEndothelial cellsCells
2022
S1453 Weight Loss in Bariatric Surgery Patients Treated at a Novel Clinic Incorporating Obesity Medicine for Treatment of Nonalcoholic Fatty Liver Disease
Ilagan-Ying Y, Schwartz A, Park E, Bollinger B, Ying L, Mehal W, Do A. S1453 Weight Loss in Bariatric Surgery Patients Treated at a Novel Clinic Incorporating Obesity Medicine for Treatment of Nonalcoholic Fatty Liver Disease. The American Journal Of Gastroenterology 2022, 117: e1043-e1044. DOI: 10.14309/01.ajg.0000862452.53915.0f.Peer-Reviewed Original Research
2020
Nonalcoholic Fatty Liver Disease in the Post Liver Transplant Patient
Batisti J, Mehal W. Nonalcoholic Fatty Liver Disease in the Post Liver Transplant Patient. Current Transplantation Reports 2020, 7: 332-339. DOI: 10.1007/s40472-020-00303-0.Peer-Reviewed Original ResearchFatty liver diseaseLiver transplantNonalcoholic steatohepatitisLiver diseasePost liver transplant patientsReviewNonalcoholic fatty liver diseaseNonalcoholic fatty liver diseaseManagement of immunosuppressionManagement of NAFLDPost-transplant populationLiver transplant patientsPost-transplant periodExcess weight gainRecent FindingsRecent studiesGraft steatosisNAFLD interventionGraft fibrosisHepatic manifestationRecurrent diseaseTransplant patientsMetabolic syndromeMedical managementRecipient factorsInsulin resistanceLT populationS1189 Incorporation of Obesity Medicine Into the Care of Patients With Nonalcoholic Fatty Liver Disease: 1-Year Interim Results
Mankash M, Kelly M, Duffy A, Mehal W, Do A. S1189 Incorporation of Obesity Medicine Into the Care of Patients With Nonalcoholic Fatty Liver Disease: 1-Year Interim Results. The American Journal Of Gastroenterology 2020, 115: s595-s595. DOI: 10.14309/01.ajg.0000706804.10023.a3.Peer-Reviewed Original Research
2019
Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease
Do A, Ilagan-Ying Y, Mehal W. Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease. Current Hepatology Reports 2019, 18: 444-454. DOI: 10.1007/s11901-019-00498-6.Peer-Reviewed Original ResearchSuccessful weight lossFatty liver diseaseWeight lossLiver diseaseReviewNonalcoholic fatty liver diseaseNonalcoholic fatty liver diseaseWeight loss medicationsCurrent medical therapyPatient-centered approachMedical therapyPatient weightPatient evaluationMultisystemic complicationsEpidemic proportionsBehavioral change goalsNAFLDMedical approachObesityDiseaseMedicationsMultimodal approachFibrosisTreatmentSteatosisComplicationsThe impact of scoring system in the evaluation of Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
Yousaf M, Chaudhary F, Mehal W. The impact of scoring system in the evaluation of Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Gastroenterology & Hepatology Open Access 2019, 10: 262-266. DOI: 10.15406/ghoa.2019.10.00392.Peer-Reviewed Original Research1056 Incorporation of Obesity Management into the Care of Patients With Nonalcoholic Steatohepatitis: The Yale Fatty Liver Disease Model
Mankash M, Kelly M, Dean J, Duffy A, Mehal W, Do A. 1056 Incorporation of Obesity Management into the Care of Patients With Nonalcoholic Steatohepatitis: The Yale Fatty Liver Disease Model. The American Journal Of Gastroenterology 2019, 114: s599-s599. DOI: 10.14309/01.ajg.0000593756.22484.ae.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseWeight loss medicationsNonalcoholic steatohepatitisBariatric surgeryWeight lossClinical characteristicsLiver diseaseObesity managementEffective treatmentDisease programsAverage age 55Meal replacement therapySurgical weight lossWeight loss optionsAlanine aminotransferase levelsChronic liver diseaseFatty liver diseaseObstructive sleep apneaManagement of patientsCare of patientsLimited efficacy dataClinical care modelsLiver disease modelAverage weight lossHepatology clinic
2018
Role of sterile inflammation in fatty liver diseases
Chen Y, Yousaf M, Mehal W. Role of sterile inflammation in fatty liver diseases. Liver Research 2018, 2: 21-29. DOI: 10.1016/j.livres.2018.02.003.Peer-Reviewed Original ResearchNon-alcoholic steatohepatitisSterile inflammationInflammatory responseTissue damageRegulatory T cellsFatty liver diseaseAnti-inflammatory effectsHepatic inflammatory responseAcute phase reactantsHigh-fat dietPropagation of inflammationSinusoidal endothelial cellsPro-inflammatory damageTrans retinoic acidGrowth factor βLiver inflammationMetabolic syndromeLiver diseaseIL-1βInflammatory cytokinesFat dietAlcohol excessFemale micePhase reactantsT cells